AbCellera Biologics
ABCL
139 hedge funds and large institutions have $275M invested in AbCellera Biologics in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 53 increasing their positions, 34 reducing their positions, and 26 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 34
3.01% less ownership
Funds ownership: 38.85% → 35.85% (-3%)
5% less funds holding
Funds holding: 147 → 139 (-8)
19% less capital invested
Capital invested by funds: $338M → $275M (-$63.3M)
31% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less call options, than puts
Call options by funds: $407K | Put options by funds: $837K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$18.6M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.09M |
| 3 |
Renaissance Technologies
New York
|
+$3.38M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.66M |
| 5 |
Two Sigma Investments
New York
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$25M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$15.7M |
| 3 |
FFVM
Founders Fund VII Management
San Francisco,
California
|
-$11.2M |
| 4 |
EAM
Exome Asset Management
New York
|
-$1.52M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.23M |
ABCL Hedge Fund Activity: Q3 2024 in Review
139 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q3 2024, worth a combined $275M — down 19% from $338M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ABCL and 18 opened new positions — a net loss of 8 holders — while 34 trimmed existing stakes and 53 added.
The largest buyer was Prosight Management, adding an estimated $18.6M. The largest seller was Baillie Gifford & Co, cutting an estimated $25M.
- 139 institutional investors held AbCellera Biologics (ABCL) as of Q3 2024, down from 147 in Q2 2024.
- Funds reported $275M of AbCellera Biologics stock for Q3 2024, down 19% quarter-over-quarter.
- 18 funds opened new AbCellera Biologics positions in Q3 2024 and 26 closed out, a net change of -8 holders.
- The largest AbCellera Biologics buyer in Q3 2024 was Prosight Management, an estimated $18.6M added.
- The largest AbCellera Biologics seller in Q3 2024 was Baillie Gifford & Co, an estimated $25M sold.
Based on aggregated 13F filings for Q3 2024.